Business Context and Reporting Period
Company: NeoGenomics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 19, 2025
Reporting Period: Specific event date of June 19, 2025, with a related press release dated June 24, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from nine to ten members.
- New Appointment: Marjorie C. Green was appointed as a director to fill the vacancy created by the board expansion.
- Term: Ms. Green will serve until the 2026 annual meeting of stockholders, or until her resignation, removal, or successor is elected.
- Compensation: Ms. Green will receive compensation consistent with the Company's existing director compensation program disclosed in the 2025 proxy statement.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, management commentary on operations, or specific risk factors. It includes a Regulation FD disclosure referencing a press release (Exhibit 99.1) regarding the board appointment, which is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release dated June 24, 2025 (Exhibit 99.1) for additional context on the appointment.
- Review the 2025 definitive proxy statement to confirm the specific compensation structure for independent directors.
- Confirm the effective date of Ms. Green's service and any potential conflicts of interest not detailed in this summary.